Julianna Olah, Win Lee Edwin Wong, Atta-Ul Raheem Rana Chaudhry, Omar Mena, Sunny X Tang
{"title":"Detecting schizophrenia, bipolar disorder, psychosis vulnerability and major depressive disorder from 5 minutes of online-collected speech.","authors":"Julianna Olah, Win Lee Edwin Wong, Atta-Ul Raheem Rana Chaudhry, Omar Mena, Sunny X Tang","doi":"10.1038/s41398-025-03433-0","DOIUrl":null,"url":null,"abstract":"<p><p>Psychosis poses substantial social and healthcare burdens. The analysis of speech is a promising approach for the diagnosis and monitoring of psychosis, capturing symptoms like thought disorder and flattened affect. Recent advancements in Natural Language Processing (NLP) methodologies enable the automated extraction of informative speech features, which has been leveraged for early psychosis detection and assessment of symptomology. However, critical gaps persist, including the absence of standardized sample collection protocols, small sample sizes, and a lack of multi-illness classification, limiting clinical applicability. Our study aimed to (1) identify an optimal assessment approach for the online and remote collection of speech, in the context of assessing the psychosis spectrum and evaluate whether a fully automated, speech-based machine learning (ML) pipeline can discriminate among different conditions on the schizophrenia-bipolar spectrum (SSD-BD-SPE), help-seeking comparison subjects (MDD), and healthy controls (HC) at varying layers of analysis and diagnostic complexity. We adopted online data collection methods to collect 20 min of speech and demographic information from individuals. Participants were categorized as \"healthy\" help-seekers (HC), having a schizophrenia-spectrum disorder (SSD), bipolar disorder (BD), major depressive disorder (MDD), or being on the psychosis spectrum with sub-clinical psychotic experiences (SPE). SPE status was determined based on self-reported clinical diagnosis and responses to the PHQ-8 and PQ-16 screening questionnaires, while other diagnoses were determined based on self-report from participants. Linguistic and paralinguistic features were extracted and ensemble learning algorithms (e.g., XGBoost) were used to train models. A 70-30% train-test split and 30-fold cross-validation was used to validate the model performance. The final analysis sample included 1140 individuals and 22,650 min of speech. Using 5 min of speech, our model could discriminate between HC and those with a serious mental illness (SSD or BD) with 86% accuracy (AUC = 0.91, Recall = 0.7, Precision = 0.98). Furthermore, our model could discern among HC, SPE, BD and SSD groups with 86% accuracy (F1 macro = 0.855, Recall Macro = 0.86, Precision Macro = 0.86). Finally, in a 5-class discrimination task including individuals with MDD, our model had 76% accuracy (F1 macro = 0.757, Recall Macro = 0.758, Precision Macro = 0.766). Our ML pipeline demonstrated disorder-specific learning, achieving excellent or good accuracy across several classification tasks. We demonstrated that the screening of mental disorders is possible via a fully automated, remote speech assessment pipeline. We tested our model on relatively high number conditions (5 classes) in the literature and in a stratified sample of psychosis spectrum, including HC, SPE, SSD and BD (4 classes). We tested our model on a large sample (N = 1150) and demonstrated best-in-class accuracy with remotely collected speech data in the psychosis spectrum, however, further clinical validation is needed to test the reliability of model performance.</p>","PeriodicalId":23278,"journal":{"name":"Translational Psychiatry","volume":"15 1","pages":"241"},"PeriodicalIF":5.8000,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255794/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41398-025-03433-0","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Psychosis poses substantial social and healthcare burdens. The analysis of speech is a promising approach for the diagnosis and monitoring of psychosis, capturing symptoms like thought disorder and flattened affect. Recent advancements in Natural Language Processing (NLP) methodologies enable the automated extraction of informative speech features, which has been leveraged for early psychosis detection and assessment of symptomology. However, critical gaps persist, including the absence of standardized sample collection protocols, small sample sizes, and a lack of multi-illness classification, limiting clinical applicability. Our study aimed to (1) identify an optimal assessment approach for the online and remote collection of speech, in the context of assessing the psychosis spectrum and evaluate whether a fully automated, speech-based machine learning (ML) pipeline can discriminate among different conditions on the schizophrenia-bipolar spectrum (SSD-BD-SPE), help-seeking comparison subjects (MDD), and healthy controls (HC) at varying layers of analysis and diagnostic complexity. We adopted online data collection methods to collect 20 min of speech and demographic information from individuals. Participants were categorized as "healthy" help-seekers (HC), having a schizophrenia-spectrum disorder (SSD), bipolar disorder (BD), major depressive disorder (MDD), or being on the psychosis spectrum with sub-clinical psychotic experiences (SPE). SPE status was determined based on self-reported clinical diagnosis and responses to the PHQ-8 and PQ-16 screening questionnaires, while other diagnoses were determined based on self-report from participants. Linguistic and paralinguistic features were extracted and ensemble learning algorithms (e.g., XGBoost) were used to train models. A 70-30% train-test split and 30-fold cross-validation was used to validate the model performance. The final analysis sample included 1140 individuals and 22,650 min of speech. Using 5 min of speech, our model could discriminate between HC and those with a serious mental illness (SSD or BD) with 86% accuracy (AUC = 0.91, Recall = 0.7, Precision = 0.98). Furthermore, our model could discern among HC, SPE, BD and SSD groups with 86% accuracy (F1 macro = 0.855, Recall Macro = 0.86, Precision Macro = 0.86). Finally, in a 5-class discrimination task including individuals with MDD, our model had 76% accuracy (F1 macro = 0.757, Recall Macro = 0.758, Precision Macro = 0.766). Our ML pipeline demonstrated disorder-specific learning, achieving excellent or good accuracy across several classification tasks. We demonstrated that the screening of mental disorders is possible via a fully automated, remote speech assessment pipeline. We tested our model on relatively high number conditions (5 classes) in the literature and in a stratified sample of psychosis spectrum, including HC, SPE, SSD and BD (4 classes). We tested our model on a large sample (N = 1150) and demonstrated best-in-class accuracy with remotely collected speech data in the psychosis spectrum, however, further clinical validation is needed to test the reliability of model performance.
期刊介绍:
Psychiatry has suffered tremendously by the limited translational pipeline. Nobel laureate Julius Axelrod''s discovery in 1961 of monoamine reuptake by pre-synaptic neurons still forms the basis of contemporary antidepressant treatment. There is a grievous gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our patients. Translational Psychiatry bridges this gap by fostering and highlighting the pathway from discovery to clinical applications, healthcare and global health. We view translation broadly as the full spectrum of work that marks the pathway from discovery to global health, inclusive. The steps of translation that are within the scope of Translational Psychiatry include (i) fundamental discovery, (ii) bench to bedside, (iii) bedside to clinical applications (clinical trials), (iv) translation to policy and health care guidelines, (v) assessment of health policy and usage, and (vi) global health. All areas of medical research, including — but not restricted to — molecular biology, genetics, pharmacology, imaging and epidemiology are welcome as they contribute to enhance the field of translational psychiatry.